BACKGROUND AND AIMS: In clinical trials, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and safety profile. Based on these findings, PCSK9 inhibitors are incorporated in updates of clinical treatment guidelines. However, trial results do not necessarily predict the effectiveness under real-world conditions. The aim of the current study is to determine the efficacy and tolerability of PCSK9 inhibitors in routine outpatient care. METHODS: The cohort comprised all patients who were prescribed evolocumab or alirocumab at the outpatient clinic of a large university hospital in the Netherlands. Eligible patients required additional lipid-lowering despite maximally tolerated statin therapy and ezetimibe, or were statin intolerant. Data were systematically collected during routine outpatient visits. RESULTS: The study included 238 patients of whom 67.2% had familial hypercholesterolemia (FH) and 42.9% were statin intolerant. The mean LDL-c reduction was 55.0% from a baseline of 4.4 mmol/L. LDL-c goals were attained by 62.3% of patients. Side effects were reported by 15.5% of patients and 2.5% discontinued treatment. No meaningful differences in efficacy or tolerability were observed between patients with FH or statin intolerance, or across treatment regimens. CONCLUSIONS: The observed lipid reductions and side effects profile of PCSK9 inhibitors in a routine care setting were comparable to observations in clinical trials.
BACKGROUND AND AIMS: In clinical trials, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and safety profile. Based on these findings, PCSK9 inhibitors are incorporated in updates of clinical treatment guidelines. However, trial results do not necessarily predict the effectiveness under real-world conditions. The aim of the current study is to determine the efficacy and tolerability of PCSK9 inhibitors in routine outpatient care. METHODS: The cohort comprised all patients who were prescribed evolocumab or alirocumab at the outpatient clinic of a large university hospital in the Netherlands. Eligible patients required additional lipid-lowering despite maximally tolerated statin therapy and ezetimibe, or were statin intolerant. Data were systematically collected during routine outpatient visits. RESULTS: The study included 238 patients of whom 67.2% had familial hypercholesterolemia (FH) and 42.9% were statin intolerant. The mean LDL-c reduction was 55.0% from a baseline of 4.4 mmol/L. LDL-c goals were attained by 62.3% of patients. Side effects were reported by 15.5% of patients and 2.5% discontinued treatment. No meaningful differences in efficacy or tolerability were observed between patients with FH or statin intolerance, or across treatment regimens. CONCLUSIONS: The observed lipid reductions and side effects profile of PCSK9 inhibitors in a routine care setting were comparable to observations in clinical trials.
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Laurenz T Fischer; Daniel A Hochfellner; Lisa Knoll; Tina Pöttler; Julia K Mader; Felix Aberer Journal: Cardiovasc Diabetol Date: 2021-04-24 Impact factor: 9.951
Authors: Krzysztof Chlebus; Barbara Cybulska; Piotr Dobrowolski; Marzena Romanowska-Kocejko; Marta Żarczyńska-Buchowiecka; Natasza Gilis-Malinowska; Aneta Stróżyk; Justyna Borowiec-Wolna; Marcin Pajkowski; Beata Bobrowska; Renata Rajtar-Salwa; Aleksandra Kwapiszewska; Małgorzata Waluś-Miarka; Magdalena Chmara; Rafał Gałąska; Maciej Małecki; Tomasz Zdrojewski; Marcin Gruchała Journal: Cardiol J Date: 2022-02-11 Impact factor: 2.737
Authors: Isabella Sudano; Francois Mach; Tiziano Moccetti; Thilo Burkard; Christian Fahe; Alain Delabays; Hans Rickli; Pierre-Frédéric Keller; Jörn Dopheide; Sereina Bodenmann; Tom Fiolka; Georg Ehret; David Spirk Journal: Front Cardiovasc Med Date: 2022-07-15
Authors: Tim Hollstein; Ursula Kassner; Thomas Grenkowitz; Friederike Schumann; Thomas Bobbert; Elisabeth Steinhagen-Thiessen Journal: Am J Cardiovasc Drugs Date: 2021-01 Impact factor: 3.571